Gilead Sciences Inc’s Chief Scientific Officer John McHutchison will leave the company next month, the company announced Wednesday. McHutchison, who is also Gilead’s head of research and development, joined the pharmaceutical giant in 2010 and was named chief scientific officer in March 2018. During his time at Gilead, he oversaw the development of several hepatitis B and C treatments, as well as the company’s expansion into oncology with the development of Zydelig.
Gilead also announced other changes to its senior leadership team: Chief Patient Officer Greg Alton and Executive Vice President of Human Resources Katie Watson will be leaving, as well. Jyoti Mehra, currently vice president of human resources, will take Watson’s place.
Shares of Gilead fell 0.4% in premarket trade on the news. The stock has gained 7% in the year to date through Tuesday, while the S&P 500 has gained 19.8%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
- Europe Markets: European stocks, Dow futures slip on virus concerns and political uncertainty - September 29, 2020
- The Moneyist: ‘He paid for all our first-class travel’: My boyfriend, 76, said he’d take care of me. I gave up everything — then he dumped me. Am I entitled to anything? - September 29, 2020
- Wizz Air initiated at outperform by Bernstein - September 29, 2020